Spots Global Cancer Trial Database for ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
Official Title: A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen
Study ID: NCT00745875
Study Description
Brief Summary: The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
research Site, Pleven, , Bulgaria
Research Site, Sofia, , Bulgaria
Research Site, Varna, , Bulgaria
Research Site, Jicin, , Czech Republic
Research Site, Prague, , Czech Republic
Research Site, Cedex, , France
Research Site, Strasbourg, , France
Research Site, Bucharest, , Romania
Research Site, Cluj-Napoca, , Romania
Research Site, Chernivtsi, , Ukraine
Research Site, Kiev, , Ukraine
Research Site, Sumy, , Ukraine
Research Site, Uzngorod, , Ukraine
Contact Details
Name: Thomas Morris, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Christos Chouaid, MD, Prof
Affiliation: Hospital Saint-Antoine, Cedex, France
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
